$KROS Keros Therapeutics, Inc. Insider Trading Week 15/2020
FREE EMAIL WATCHDOG
Get free email notifications about insider trading in Keros Therapeutics, Inc..
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insiders | Insider Transactions | Monthly Overview | Weekly Overview
Overview of insider trading in Keros Therapeutics, Inc. in week 15/2020.
| Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Apr 13 2020 | KROS | Keros Therapeutics ... | Arkin Bio Ventures Limited Par ... | 10% Owner | Option Exercise | C | 0.00 | 167,537 | 0 | 0 | |
| Apr 13 2020 | KROS | Keros Therapeutics ... | Arkin Bio Ventures Limited Par ... | 10% Owner | Option Exercise | C | 0.00 | 343,270 | 0 | 0 | |
| Apr 13 2020 | KROS | Keros Therapeutics ... | Arkin Bio Ventures Limited Par ... | 10% Owner | Option Exercise | C | 0.00 | 1,382,295 | 0 | 0 | |
| Apr 13 2020 | KROS | Keros Therapeutics ... | Arkin Bio Ventures Limited Par ... | 10% Owner | Buy | P | 16.00 | 120,000 | 1,920,000 | 2,013,102 | 1.9 M to 2 M (+6.34 %) |
| Apr 13 2020 | KROS | Keros Therapeutics ... | Arkin Bio Ventures Limited Par ... | 10% Owner | Buy | C | 0.00 | 167,537 | 0 | 1,893,102 | 1.7 M to 1.9 M (+9.71 %) |
| Apr 13 2020 | KROS | Keros Therapeutics ... | Arkin Bio Ventures Limited Par ... | 10% Owner | Buy | C | 0.00 | 343,270 | 0 | 1,725,565 | 1.4 M to 1.7 M (+24.83 %) |
| Apr 13 2020 | KROS | Keros Therapeutics ... | Arkin Bio Ventures Limited Par ... | 10% Owner | Buy | C | 0.00 | 1,382,295 | 0 | 1,382,295 | 0 to 1.4 M |
| Apr 13 2020 | KROS | Keros Therapeutics ... | Seehra Jasbir | Chief Executive Off ... | Option Exercise | C | 0.00 | 11,169 | 0 | 0 | |
| Apr 13 2020 | KROS | Keros Therapeutics ... | Seehra Jasbir | Chief Executive Off ... | Buy | P | 16.00 | 20,000 | 320,000 | 243,856 | 223.9 K to 243.9 K (+8.93 %) |
| Apr 13 2020 | KROS | Keros Therapeutics ... | Seehra Jasbir | Chief Executive Off ... | Buy | C | 0.00 | 11,169 | 0 | 223,856 | 212.7 K to 223.9 K (+5.25 %) |
| Apr 13 2020 | KROS | Keros Therapeutics ... | Pontifax Management 4 G.P. (20 ... | 10% Owner | Option Exercise | C | 0.00 | 36,858 | 0 | 0 | |
| Apr 13 2020 | KROS | Keros Therapeutics ... | Pontifax Management 4 G.P. (20 ... | 10% Owner | Option Exercise | C | 0.00 | 79,653 | 0 | 0 | |
| Apr 13 2020 | KROS | Keros Therapeutics ... | Pontifax Management 4 G.P. (20 ... | 10% Owner | Option Exercise | C | 0.00 | 88,460 | 0 | 0 | |
| Apr 13 2020 | KROS | Keros Therapeutics ... | Pontifax Management 4 G.P. (20 ... | 10% Owner | Option Exercise | C | 0.00 | 163,612 | 0 | 0 | |
| Apr 13 2020 | KROS | Keros Therapeutics ... | Pontifax Management 4 G.P. (20 ... | 10% Owner | Option Exercise | C | 0.00 | 68,654 | 0 | 0 | |
| Apr 13 2020 | KROS | Keros Therapeutics ... | Pontifax Management 4 G.P. (20 ... | 10% Owner | Option Exercise | C | 0.00 | 91,538 | 0 | 0 | |
| Apr 13 2020 | KROS | Keros Therapeutics ... | Pontifax Management 4 G.P. (20 ... | 10% Owner | Option Exercise | C | 0.00 | 82,425 | 0 | 0 | |
| Apr 13 2020 | KROS | Keros Therapeutics ... | Pontifax Management 4 G.P. (20 ... | 10% Owner | Option Exercise | C | 0.00 | 169,307 | 0 | 0 | |
| Apr 13 2020 | KROS | Keros Therapeutics ... | Pontifax Management 4 G.P. (20 ... | 10% Owner | Option Exercise | C | 0.00 | 737,226 | 0 | 0 | |
| Apr 13 2020 | KROS | Keros Therapeutics ... | Pontifax Management 4 G.P. (20 ... | 10% Owner | Option Exercise | C | 0.00 | 663,825 | 0 | 0 | |
| Apr 13 2020 | KROS | Keros Therapeutics ... | Pontifax Management 4 G.P. (20 ... | 10% Owner | Option Exercise | C | 0.00 | 1,363,542 | 0 | 0 | |
| Apr 13 2020 | KROS | Keros Therapeutics ... | Pontifax Management 4 G.P. (20 ... | 10% Owner | Buy | P | 16.00 | 43,750 | 700,000 | 149,262 | 105.5 K to 149.3 K (+41.46 %) |
| Apr 13 2020 | KROS | Keros Therapeutics ... | Pontifax Management 4 G.P. (20 ... | 10% Owner | Buy | P | 16.00 | 105,000 | 1,680,000 | 1,213,926 | 1.1 M to 1.2 M (+9.47 %) |
| Apr 13 2020 | KROS | Keros Therapeutics ... | Pontifax Management 4 G.P. (20 ... | 10% Owner | Buy | P | 16.00 | 94,546 | 1,512,736 | 1,109,802 | 1 M to 1.1 M (+9.31 %) |
| Apr 13 2020 | KROS | Keros Therapeutics ... | Pontifax Management 4 G.P. (20 ... | 10% Owner | Buy | P | 16.00 | 194,203 | 3,107,248 | 2,261,517 | 2.1 M to 2.3 M (+9.39 %) |
| Apr 13 2020 | KROS | Keros Therapeutics ... | Pontifax Management 4 G.P. (20 ... | 10% Owner | Buy | C | 0.00 | 36,858 | 0 | 105,512 | 68.7 K to 105.5 K (+53.69 %) |
| Apr 13 2020 | KROS | Keros Therapeutics ... | Pontifax Management 4 G.P. (20 ... | 10% Owner | Buy | C | 0.00 | 79,653 | 0 | 1,108,926 | 1 M to 1.1 M (+7.74 %) |
| Apr 13 2020 | KROS | Keros Therapeutics ... | Pontifax Management 4 G.P. (20 ... | 10% Owner | Buy | C | 0.00 | 88,460 | 0 | 1,015,256 | 926.8 K to 1 M (+9.54 %) |
| Apr 13 2020 | KROS | Keros Therapeutics ... | Pontifax Management 4 G.P. (20 ... | 10% Owner | Buy | C | 0.00 | 163,612 | 0 | 2,067,314 | 1.9 M to 2.1 M (+8.59 %) |
| Apr 13 2020 | KROS | Keros Therapeutics ... | Pontifax Management 4 G.P. (20 ... | 10% Owner | Buy | C | 0.00 | 68,654 | 0 | 68,654 | 0 to 68.7 K |
| Apr 13 2020 | KROS | Keros Therapeutics ... | Pontifax Management 4 G.P. (20 ... | 10% Owner | Buy | C | 0.00 | 91,538 | 0 | 1,029,273 | 937.7 K to 1 M (+9.76 %) |
| Apr 13 2020 | KROS | Keros Therapeutics ... | Pontifax Management 4 G.P. (20 ... | 10% Owner | Buy | C | 0.00 | 82,425 | 0 | 926,796 | 844.4 K to 926.8 K (+9.76 %) |
| Apr 13 2020 | KROS | Keros Therapeutics ... | Pontifax Management 4 G.P. (20 ... | 10% Owner | Buy | C | 0.00 | 169,307 | 0 | 1,903,702 | 1.7 M to 1.9 M (+9.76 %) |
| Apr 13 2020 | KROS | Keros Therapeutics ... | Pontifax Management 4 G.P. (20 ... | 10% Owner | Buy | C | 0.00 | 737,226 | 0 | 937,735 | 200.5 K to 937.7 K (+367.68 %) |
| Apr 13 2020 | KROS | Keros Therapeutics ... | Pontifax Management 4 G.P. (20 ... | 10% Owner | Buy | C | 0.00 | 663,825 | 0 | 844,371 | 180.5 K to 844.4 K (+367.68 %) |
| Apr 13 2020 | KROS | Keros Therapeutics ... | Pontifax Management 4 G.P. (20 ... | 10% Owner | Buy | C | 0.00 | 1,363,542 | 0 | 1,734,395 | 370.9 K to 1.7 M (+367.68 %) |
| Apr 13 2020 | KROS | Keros Therapeutics ... | ORBIMED ADVISORS LLC | Director | Option Exercise | C | 0.00 | 148,922 | 0 | 0 | |
| Apr 13 2020 | KROS | Keros Therapeutics ... | ORBIMED ADVISORS LLC | Director | Option Exercise | C | 0.00 | 744,612 | 0 | 0 | |
| Apr 13 2020 | KROS | Keros Therapeutics ... | ORBIMED ADVISORS LLC | Director | Buy | P | 16.00 | 375,200 | 6,003,200 | 1,119,812 | 744.6 K to 1.1 M (+50.39 %) |
| Apr 13 2020 | KROS | Keros Therapeutics ... | ORBIMED ADVISORS LLC | Director | Buy | C | 0.00 | 148,922 | 0 | 148,922 | 0 to 148.9 K |
| Apr 13 2020 | KROS | Keros Therapeutics ... | ORBIMED ADVISORS LLC | Director | Buy | C | 0.00 | 744,612 | 0 | 744,612 | 0 to 744.6 K |
| Apr 13 2020 | KROS | Keros Therapeutics ... | Nussbaum Ran | Director | Option Exercise | C | 0.00 | 36,858 | 0 | 0 | |
| Apr 13 2020 | KROS | Keros Therapeutics ... | Nussbaum Ran | Director | Option Exercise | C | 0.00 | 79,653 | 0 | 0 | |
| Apr 13 2020 | KROS | Keros Therapeutics ... | Nussbaum Ran | Director | Option Exercise | C | 0.00 | 88,460 | 0 | 0 | |
| Apr 13 2020 | KROS | Keros Therapeutics ... | Nussbaum Ran | Director | Option Exercise | C | 0.00 | 163,612 | 0 | 0 | |
| Apr 13 2020 | KROS | Keros Therapeutics ... | Nussbaum Ran | Director | Option Exercise | C | 0.00 | 68,654 | 0 | 0 | |
| Apr 13 2020 | KROS | Keros Therapeutics ... | Nussbaum Ran | Director | Option Exercise | C | 0.00 | 91,538 | 0 | 0 | |
| Apr 13 2020 | KROS | Keros Therapeutics ... | Nussbaum Ran | Director | Option Exercise | C | 0.00 | 82,425 | 0 | 0 | |
| Apr 13 2020 | KROS | Keros Therapeutics ... | Nussbaum Ran | Director | Option Exercise | C | 0.00 | 169,307 | 0 | 0 | |
| Apr 13 2020 | KROS | Keros Therapeutics ... | Nussbaum Ran | Director | Option Exercise | C | 0.00 | 737,226 | 0 | 0 | |
| Apr 13 2020 | KROS | Keros Therapeutics ... | Nussbaum Ran | Director | Option Exercise | C | 0.00 | 663,825 | 0 | 0 | |
| Apr 13 2020 | KROS | Keros Therapeutics ... | Nussbaum Ran | Director | Option Exercise | C | 0.00 | 1,363,542 | 0 | 0 | |
| Apr 13 2020 | KROS | Keros Therapeutics ... | Nussbaum Ran | Director | Buy | P | 16.00 | 43,750 | 700,000 | 149,262 | 105.5 K to 149.3 K (+41.46 %) |
| Apr 13 2020 | KROS | Keros Therapeutics ... | Nussbaum Ran | Director | Buy | P | 16.00 | 105,000 | 1,680,000 | 1,213,926 | 1.1 M to 1.2 M (+9.47 %) |
| Apr 13 2020 | KROS | Keros Therapeutics ... | Nussbaum Ran | Director | Buy | P | 16.00 | 94,546 | 1,512,736 | 1,109,802 | 1 M to 1.1 M (+9.31 %) |
| Apr 13 2020 | KROS | Keros Therapeutics ... | Nussbaum Ran | Director | Buy | P | 16.00 | 194,203 | 3,107,248 | 2,261,517 | 2.1 M to 2.3 M (+9.39 %) |
| Apr 13 2020 | KROS | Keros Therapeutics ... | Nussbaum Ran | Director | Buy | C | 0.00 | 36,858 | 0 | 105,512 | 68.7 K to 105.5 K (+53.69 %) |
| Apr 13 2020 | KROS | Keros Therapeutics ... | Nussbaum Ran | Director | Buy | C | 0.00 | 79,653 | 0 | 1,108,926 | 1 M to 1.1 M (+7.74 %) |
| Apr 13 2020 | KROS | Keros Therapeutics ... | Nussbaum Ran | Director | Buy | C | 0.00 | 88,460 | 0 | 1,015,256 | 926.8 K to 1 M (+9.54 %) |
| Apr 13 2020 | KROS | Keros Therapeutics ... | Nussbaum Ran | Director | Buy | C | 0.00 | 163,612 | 0 | 2,067,314 | 1.9 M to 2.1 M (+8.59 %) |
| Apr 13 2020 | KROS | Keros Therapeutics ... | Nussbaum Ran | Director | Buy | C | 0.00 | 68,654 | 0 | 68,654 | 0 to 68.7 K |
| Apr 13 2020 | KROS | Keros Therapeutics ... | Nussbaum Ran | Director | Buy | C | 0.00 | 91,538 | 0 | 1,029,273 | 937.7 K to 1 M (+9.76 %) |
| Apr 13 2020 | KROS | Keros Therapeutics ... | Nussbaum Ran | Director | Buy | C | 0.00 | 82,425 | 0 | 926,796 | 844.4 K to 926.8 K (+9.76 %) |
| Apr 13 2020 | KROS | Keros Therapeutics ... | Nussbaum Ran | Director | Buy | C | 0.00 | 169,307 | 0 | 1,903,702 | 1.7 M to 1.9 M (+9.76 %) |
| Apr 13 2020 | KROS | Keros Therapeutics ... | Nussbaum Ran | Director | Buy | C | 0.00 | 737,226 | 0 | 937,735 | 200.5 K to 937.7 K (+367.68 %) |
| Apr 13 2020 | KROS | Keros Therapeutics ... | Nussbaum Ran | Director | Buy | C | 0.00 | 663,825 | 0 | 844,371 | 180.5 K to 844.4 K (+367.68 %) |
| Apr 13 2020 | KROS | Keros Therapeutics ... | Nussbaum Ran | Director | Buy | C | 0.00 | 1,363,542 | 0 | 1,734,395 | 370.9 K to 1.7 M (+367.68 %) |
| Apr 13 2020 | KROS | Keros Therapeutics ... | Lazarus Alon | Director | Option Exercise | C | 0.00 | 167,537 | 0 | 0 | |
| Apr 13 2020 | KROS | Keros Therapeutics ... | Lazarus Alon | Director | Option Exercise | C | 0.00 | 343,270 | 0 | 0 | |
| Apr 13 2020 | KROS | Keros Therapeutics ... | Lazarus Alon | Director | Option Exercise | C | 0.00 | 1,382,295 | 0 | 0 | |
| Apr 13 2020 | KROS | Keros Therapeutics ... | Lazarus Alon | Director | Buy | P | 16.00 | 120,000 | 1,920,000 | 2,013,102 | 1.9 M to 2 M (+6.34 %) |
| Apr 13 2020 | KROS | Keros Therapeutics ... | Lazarus Alon | Director | Buy | C | 0.00 | 167,537 | 0 | 1,893,102 | 1.7 M to 1.9 M (+9.71 %) |
| Apr 13 2020 | KROS | Keros Therapeutics ... | Lazarus Alon | Director | Buy | C | 0.00 | 343,270 | 0 | 1,725,565 | 1.4 M to 1.7 M (+24.83 %) |
| Apr 13 2020 | KROS | Keros Therapeutics ... | Lazarus Alon | Director | Buy | C | 0.00 | 1,382,295 | 0 | 1,382,295 | 0 to 1.4 M |
| Apr 13 2020 | KROS | Keros Therapeutics ... | Knowles Julius | Director | Option Exercise | C | 0.00 | 44,676 | 0 | 0 | |
| Apr 13 2020 | KROS | Keros Therapeutics ... | Knowles Julius | Director | Option Exercise | C | 0.00 | 67,015 | 0 | 0 | |
| Apr 13 2020 | KROS | Keros Therapeutics ... | Knowles Julius | Director | Option Exercise | C | 0.00 | 137,308 | 0 | 0 | |
| Apr 13 2020 | KROS | Keros Therapeutics ... | Knowles Julius | Director | Option Exercise | C | 0.00 | 205,962 | 0 | 0 | |
| Apr 13 2020 | KROS | Keros Therapeutics ... | Knowles Julius | Director | Option Exercise | C | 0.00 | 184,305 | 0 | 0 | |
| Apr 13 2020 | KROS | Keros Therapeutics ... | Knowles Julius | Director | Option Exercise | C | 0.00 | 276,459 | 0 | 0 | |
| Apr 13 2020 | KROS | Keros Therapeutics ... | Knowles Julius | Director | Buy | C | 0.00 | 44,676 | 0 | 458,442 | 413.8 K to 458.4 K (+10.80 %) |
| Apr 13 2020 | KROS | Keros Therapeutics ... | Knowles Julius | Director | Buy | C | 0.00 | 67,015 | 0 | 687,665 | 620.7 K to 687.7 K (+10.80 %) |
| Apr 13 2020 | KROS | Keros Therapeutics ... | Knowles Julius | Director | Buy | C | 0.00 | 137,308 | 0 | 413,766 | 276.5 K to 413.8 K (+49.67 %) |
| Apr 13 2020 | KROS | Keros Therapeutics ... | Knowles Julius | Director | Buy | C | 0.00 | 205,962 | 0 | 620,650 | 414.7 K to 620.7 K (+49.67 %) |
| Apr 13 2020 | KROS | Keros Therapeutics ... | Knowles Julius | Director | Buy | C | 0.00 | 184,305 | 0 | 276,458 | 92.2 K to 276.5 K (+200.00 %) |
| Apr 13 2020 | KROS | Keros Therapeutics ... | Knowles Julius | Director | Buy | C | 0.00 | 276,459 | 0 | 414,688 | 138.2 K to 414.7 K (+200.00 %) |
| Apr 13 2020 | KROS | Keros Therapeutics ... | Kariv Tomer | Director | Option Exercise | C | 0.00 | 36,858 | 0 | 0 | |
| Apr 13 2020 | KROS | Keros Therapeutics ... | Kariv Tomer | Director | Option Exercise | C | 0.00 | 79,653 | 0 | 0 | |
| Apr 13 2020 | KROS | Keros Therapeutics ... | Kariv Tomer | Director | Option Exercise | C | 0.00 | 88,460 | 0 | 0 | |
| Apr 13 2020 | KROS | Keros Therapeutics ... | Kariv Tomer | Director | Option Exercise | C | 0.00 | 163,612 | 0 | 0 | |
| Apr 13 2020 | KROS | Keros Therapeutics ... | Kariv Tomer | Director | Option Exercise | C | 0.00 | 68,654 | 0 | 0 | |
| Apr 13 2020 | KROS | Keros Therapeutics ... | Kariv Tomer | Director | Option Exercise | C | 0.00 | 91,538 | 0 | 0 | |
| Apr 13 2020 | KROS | Keros Therapeutics ... | Kariv Tomer | Director | Option Exercise | C | 0.00 | 82,425 | 0 | 0 | |
| Apr 13 2020 | KROS | Keros Therapeutics ... | Kariv Tomer | Director | Option Exercise | C | 0.00 | 169,307 | 0 | 0 | |
| Apr 13 2020 | KROS | Keros Therapeutics ... | Kariv Tomer | Director | Option Exercise | C | 0.00 | 737,226 | 0 | 0 | |
| Apr 13 2020 | KROS | Keros Therapeutics ... | Kariv Tomer | Director | Option Exercise | C | 0.00 | 663,825 | 0 | 0 | |
| Apr 13 2020 | KROS | Keros Therapeutics ... | Kariv Tomer | Director | Option Exercise | C | 0.00 | 1,363,542 | 0 | 0 | |
| Apr 13 2020 | KROS | Keros Therapeutics ... | Kariv Tomer | Director | Buy | P | 16.00 | 43,750 | 700,000 | 149,262 | 105.5 K to 149.3 K (+41.46 %) |
| Apr 13 2020 | KROS | Keros Therapeutics ... | Kariv Tomer | Director | Buy | P | 16.00 | 105,000 | 1,680,000 | 1,213,926 | 1.1 M to 1.2 M (+9.47 %) |
| Apr 13 2020 | KROS | Keros Therapeutics ... | Kariv Tomer | Director | Buy | P | 16.00 | 94,546 | 1,512,736 | 1,109,802 | 1 M to 1.1 M (+9.31 %) |
| Apr 13 2020 | KROS | Keros Therapeutics ... | Kariv Tomer | Director | Buy | P | 16.00 | 194,203 | 3,107,248 | 2,261,517 | 2.1 M to 2.3 M (+9.39 %) |
| Apr 13 2020 | KROS | Keros Therapeutics ... | Kariv Tomer | Director | Buy | C | 0.00 | 36,858 | 0 | 105,512 | 68.7 K to 105.5 K (+53.69 %) |
| Apr 13 2020 | KROS | Keros Therapeutics ... | Kariv Tomer | Director | Buy | C | 0.00 | 79,653 | 0 | 1,108,926 | 1 M to 1.1 M (+7.74 %) |
| Apr 13 2020 | KROS | Keros Therapeutics ... | Kariv Tomer | Director | Buy | C | 0.00 | 88,460 | 0 | 1,015,256 | 926.8 K to 1 M (+9.54 %) |
| Apr 13 2020 | KROS | Keros Therapeutics ... | Kariv Tomer | Director | Buy | C | 0.00 | 163,612 | 0 | 2,067,314 | 1.9 M to 2.1 M (+8.59 %) |
| Apr 13 2020 | KROS | Keros Therapeutics ... | Kariv Tomer | Director | Buy | C | 0.00 | 68,654 | 0 | 68,654 | 0 to 68.7 K |
| Apr 13 2020 | KROS | Keros Therapeutics ... | Kariv Tomer | Director | Buy | C | 0.00 | 91,538 | 0 | 1,029,273 | 937.7 K to 1 M (+9.76 %) |
| Apr 13 2020 | KROS | Keros Therapeutics ... | Kariv Tomer | Director | Buy | C | 0.00 | 82,425 | 0 | 926,796 | 844.4 K to 926.8 K (+9.76 %) |
| Apr 13 2020 | KROS | Keros Therapeutics ... | Kariv Tomer | Director | Buy | C | 0.00 | 169,307 | 0 | 1,903,702 | 1.7 M to 1.9 M (+9.76 %) |
| Apr 13 2020 | KROS | Keros Therapeutics ... | Kariv Tomer | Director | Buy | C | 0.00 | 737,226 | 0 | 937,735 | 200.5 K to 937.7 K (+367.68 %) |
| Apr 13 2020 | KROS | Keros Therapeutics ... | Kariv Tomer | Director | Buy | C | 0.00 | 663,825 | 0 | 844,371 | 180.5 K to 844.4 K (+367.68 %) |
| Apr 13 2020 | KROS | Keros Therapeutics ... | Kariv Tomer | Director | Buy | C | 0.00 | 1,363,542 | 0 | 1,734,395 | 370.9 K to 1.7 M (+367.68 %) |
| Apr 13 2020 | KROS | Keros Therapeutics ... | GORDON CARL L | Director | Option Exercise | C | 0.00 | 148,922 | 0 | 0 | |
| Apr 13 2020 | KROS | Keros Therapeutics ... | GORDON CARL L | Director | Option Exercise | C | 0.00 | 744,612 | 0 | 0 | |
| Apr 13 2020 | KROS | Keros Therapeutics ... | GORDON CARL L | Director | Buy | P | 16.00 | 375,200 | 6,003,200 | 1,119,812 | 744.6 K to 1.1 M (+50.39 %) |
| Apr 13 2020 | KROS | Keros Therapeutics ... | GORDON CARL L | Director | Buy | C | 0.00 | 148,922 | 0 | 148,922 | 0 to 148.9 K |
| Apr 13 2020 | KROS | Keros Therapeutics ... | GORDON CARL L | Director | Buy | C | 0.00 | 744,612 | 0 | 744,612 | 0 to 744.6 K |